Certain information has been omitted from this exhibit in places marked “[***]” because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed.Commercialization and License Agreement • March 13th, 2020 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Commercialization and License Agreement (this “Agreement”) is made as of November 5, 2019 (the “Effective Date”) by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”), having a place of business at 4505 Emperor Boulevard, Suite 200, Durham, NC 27703, USA, and Torii Pharmaceutical Co., Ltd., a corporation organized under the laws of Japan (“Torii”), having a place of business at 4-1 Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo, Japan. BioCryst and Torii are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
AGREEMENTAgreement • March 13th, 2020 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This AGREEMENT (“Agreement”) is made and entered into by Thomas R. Staab II (“Employee”) and BioCryst Pharmaceuticals, Inc. (“the Company”).
